J
Jonathan A. Fletcher
Researcher at Brigham and Women's Hospital
Publications - 426
Citations - 57627
Jonathan A. Fletcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: GiST & PDGFRA. The author has an hindex of 109, co-authored 413 publications receiving 53642 citations. Previous affiliations of Jonathan A. Fletcher include Albany Medical College & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
KIT mutations are common in testicular seminomas.
Kathleen Kemmer,Christopher L. Corless,Jonathan A. Fletcher,Laura McGreevey,Andrea Haley,Diana J. Griffith,Oscar W. Cummings,Cecily L. Wait,Ajia Town,Michael Heinrich +9 more
TL;DR: It is suggested that activating KIT mutations may contribute to tumorigenesis in a subset of seminomas, but are not involved in NSGCT.
Journal ArticleDOI
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
Anette Duensing,Anette Duensing,Fabiola Medeiros,Bryna McConarty,Nora E. Joseph,Dipak Panigrahy,Samuel Singer,Christopher D.M. Fletcher,George D. Demetri,Jonathan A. Fletcher,Jonathan A. Fletcher +10 more
TL;DR: In this article, the authors evaluated KIT downstream signaling profiles in 15 primary GISTs with mutations in KIT exons 9, 11, 13, and 17, and in two human GIST cell lines.
Journal ArticleDOI
Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)
Michael Heinrich,Grant A. McArthur,George D. Demetri,Heikki Joensuu,Petri Bono,Richard Herrmann,Hal Hirte,Sara Cresta,D. Bradley Koslin,Christopher L. Corless,Stephan Dirnhofer,Allan T. van Oosterom,Zariana Nikolova,Sasa Dimitrijevic,Jonathan A. Fletcher +14 more
TL;DR: Imatinib response in AF patients may be mediated by inhibition of PDGFRB kinase activity, and imatinib is an active agent in the treatment of advanced AF.
Journal ArticleDOI
Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein
Jeffrey S. Ross,Jeffrey S. Ross,Jonathan A. Fletcher,Kenneth J. Bloom,Gerald P. Linette,Gerald P. Linette,James Stec,W. Fraser Symmans,Lajos Pusztai,Gabriel N. Hortobagyi +9 more
TL;DR: A review of 80 published studies encompassing more than 25,000 patients designed to consider the relative advantages and disadvantages of the various methods of measuring HER-2/neu in clinical breast cancer specimens is presented in this paper.
Journal Article
HER-2/neu (c-erb-B2) gene and protein in breast cancer.
TL;DR: The potential value of HER-2/neu protein status for the prediction of response to therapy in breast cancer is presented for standard hormonal therapy, cytotoxic chemotherapy, and radiation therapy and the status of serum-based testing for circulating HER- 2/neU receptor protein and its ability to predict disease outcome and therapy response is evaluated.